Loading stock data…
Centessa Pharmaceuticals plc (CNTA)
$40.50
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Centessa Pharmaceuticals plc in the Healthcare sector is trading at $40.50 with a market capitalization of $6.1B. Wall Street consensus targets $40.25 (4 analysts), implying a -0.6% move over the next 12 months. The stock is currently near its 52-week high of $40.56, remaining 37.1% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0↓ | $15.00M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$79.77M↓ | -$68.47M↓ | -$53.79M↑ | -$54.65M↓ | -$30.78M |
| Net Income | -$79.24M↓ | -$66.16M↓ | -$54.89M↓ | -$50.34M↓ | -$26.14M |
Peer Comparison
JNJUNHPFE
Fundamentals
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.14B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-51.43%
Volume
Today's trading volume
11.27M
Recent News
Eli Lilly and Company (LLY) Up More Than 6% Over the Past Month, Can it Move Higher?
Eli Lilly and Company (NYSE:LLY) is one of the Stocks That Will Make You Rich Over the Next 3 Years. Eli Lilly and Company (NYSE:LLY) has gained roughly 6% over the past 30 days, and the Street expects more than 13.6% upside from the current level. Recently, on June 25, Leerink analyst David Risinger raised […]
Eli Lilly (LLY) Acquires Centessa Pharmaceuticals to Advance Orexin Receptor 2 Agonists
Eli Lilly and Company (NYSE:LLY) is one of the best stocks for beginners to buy now. On June 24, Eli Lilly completed its acquisition of Centessa Pharmaceuticals, aiming to advance the development of orexin receptor 2 agonists. This new class of medicine is designed to treat narcolepsy and other sleep-wake disorders by targeting the brain’s […]
Sector Update: Healthcare Stocks Advance Late Afternoon
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index adding 0.8% a
Here is Why Eli Lilly (LLY) is One of the Best Stocks to Buy for the Next 15 Years
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for the next 15 years. On May 7, Eli Lilly executed its largest bond issuance to date, selling $9 billion in investment-grade debt to fund a recent surge in acquisitions. The offering, which initially targeted $8 billion, saw high investor demand following […]
Update: Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions
(Updates with the company's response in the fourth paragraph.) Eli Lilly (LLY) is looking to rais